U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Ovarian serous adenocarcinoma

MedGen UID:
233278
•Concept ID:
C1335177
•
Neoplastic Process
Synonyms: malignant ovarian serous tumour; Ovarian Serous Adenocarcinoma; ovarian serous adenocarcinoma; Ovarian Serous Carcinoma; ovarian serous carcinoma; ovary serous adenocarcinoma; Serous Adenocarcinoma of Ovary; serous adenocarcinoma of ovary; Serous Adenocarcinoma of the Ovary; serous adenocarcinoma of the ovary; Serous Carcinoma of Ovary; serous carcinoma of ovary; Serous Carcinoma of the Ovary; serous carcinoma of the ovary; serous ovarian cancer
 
Monarch Initiative: MONDO:0005211

Definition

An adenocarcinoma that arises from the ovary and is characterized by the presence of malignant epithelial cells that, in well differentiated tumors, resemble the epithelium of the fallopian tube or, in poorly differentiated tumors, show anaplastic features and marked nuclear atypia. [from NCI]

Professional guidelines

PubMed

Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatin.
Soyama H, Miyamoto M, Takano M, Aoyama T, Matsuura H, Sakamoto T, Takasaki K, Kuwahara M, Kato K, Yoshikawa T, Iwahashi H, Tsuda H, Furuya K
Med Oncol 2017 Nov 22;34(12):201. doi: 10.1007/s12032-017-1058-3. PMID: 29168038
Successful surgical treatment and chemotherapy for ovarian cancer in a patient with idiopathic thrombocytopenic purpura.
Wakana K, Yasugi T, Nako Y, Nei T, Ozaki Y, Mizutani K
Int J Clin Oncol 2011 Aug;16(4):447-9. Epub 2010 Dec 4 doi: 10.1007/s10147-010-0149-3. PMID: 21132452
HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab.
Fujimura M, Katsumata N, Tsuda H, Uchi N, Miyazaki S, Hidaka T, Sakai M, Saito S
Jpn J Cancer Res 2002 Nov;93(11):1250-7. doi: 10.1111/j.1349-7006.2002.tb01231.x. PMID: 12460467Free PMC Article

Recent clinical studies

Etiology

Spectrum of BRCA1/2 Mutations in Romanian Breast and Ovarian Cancer Patients.
Vidra R, Ciuleanu TE, Nemeș A, Pascu O, Heroiu AM, Antone N, Vidrean AI, Oprean CM, Pop LA, Berindan-Neagoe I, Eniu R, Eniu A
Int J Environ Res Public Health 2022 Apr 4;19(7) doi: 10.3390/ijerph19074314. PMID: 35409996Free PMC Article
Dysregulation of X chromosome inactivation in high grade ovarian serous adenocarcinoma.
Kang J, Lee HJ, Kim J, Lee JJ, Maeng LS
PLoS One 2015;10(3):e0118927. Epub 2015 Mar 5 doi: 10.1371/journal.pone.0118927. PMID: 25742136Free PMC Article
Immunophenotype and human papillomavirus status of serous adenocarcinoma of the uterine cervix.
Togami S, Sasajima Y, Kasamatsu T, Oda-Otomo R, Okada S, Ishikawa M, Ikeda S, Kato T, Tsuda H
Pathol Oncol Res 2015 Apr;21(2):487-94. Epub 2014 Nov 5 doi: 10.1007/s12253-014-9854-y. PMID: 25370301
Anaesthetic technique may affect prognosis for ovarian serous adenocarcinoma: a retrospective analysis.
Lin L, Liu C, Tan H, Ouyang H, Zhang Y, Zeng W
Br J Anaesth 2011 Jun;106(6):814-22. Epub 2011 Mar 24 doi: 10.1093/bja/aer055. PMID: 21436156
The fallopian tube: primary site of most pelvic high-grade serous carcinomas.
Salvador S, Gilks B, Köbel M, Huntsman D, Rosen B, Miller D
Int J Gynecol Cancer 2009 Jan;19(1):58-64. doi: 10.1111/IGC.0b013e318199009c. PMID: 19258943

Diagnosis

Spectrum of BRCA1/2 Mutations in Romanian Breast and Ovarian Cancer Patients.
Vidra R, Ciuleanu TE, Nemeș A, Pascu O, Heroiu AM, Antone N, Vidrean AI, Oprean CM, Pop LA, Berindan-Neagoe I, Eniu R, Eniu A
Int J Environ Res Public Health 2022 Apr 4;19(7) doi: 10.3390/ijerph19074314. PMID: 35409996Free PMC Article
Synchronous Cervical Adenocarcinoma and Ovarian Serous Adenocarcinoma-A Case Report and Literature Review.
Bacalbasa N, Balescu IC, Diaconu C, Dima S, Iliescu L, Vilcu M, Filipescu A, Halmaciu I, Cretoiu D, Brezean I
Medicina (Kaunas) 2020 Mar 29;56(4) doi: 10.3390/medicina56040152. PMID: 32235322Free PMC Article
Expression of Interactive Genes Associated with Apoptosis and Their Prognostic Value for Ovarian Serous Adenocarcinoma.
Shin K, Kim KH, Yoon MS, Suh DS, Lee JY, Kim A, Eo W
Adv Clin Exp Med 2016 May-Jun;25(3):513-21. doi: 10.17219/acem/62540. PMID: 27629740
DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.
Yamaguchi N, Mimoto R, Yanaihara N, Imawari Y, Hirooka S, Okamoto A, Yoshida K
Tumour Biol 2015 Aug;36(8):5913-23. Epub 2015 Feb 25 doi: 10.1007/s13277-015-3264-y. PMID: 25712377
Spectrin αII and βII tetramers contribute to platinum anticancer drug resistance in ovarian serous adenocarcinoma.
Maeda O, Shibata K, Hosono S, Fujiwara S, Kajiyama H, Ino K, Nawa A, Tamakoshi K, Kikkawa F
Int J Cancer 2012 Jan 1;130(1):113-21. Epub 2011 Apr 25 doi: 10.1002/ijc.25983. PMID: 21328338

Therapy

Dysregulation of X chromosome inactivation in high grade ovarian serous adenocarcinoma.
Kang J, Lee HJ, Kim J, Lee JJ, Maeng LS
PLoS One 2015;10(3):e0118927. Epub 2015 Mar 5 doi: 10.1371/journal.pone.0118927. PMID: 25742136Free PMC Article
DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.
Yamaguchi N, Mimoto R, Yanaihara N, Imawari Y, Hirooka S, Okamoto A, Yoshida K
Tumour Biol 2015 Aug;36(8):5913-23. Epub 2015 Feb 25 doi: 10.1007/s13277-015-3264-y. PMID: 25712377
Spectrin αII and βII tetramers contribute to platinum anticancer drug resistance in ovarian serous adenocarcinoma.
Maeda O, Shibata K, Hosono S, Fujiwara S, Kajiyama H, Ino K, Nawa A, Tamakoshi K, Kikkawa F
Int J Cancer 2012 Jan 1;130(1):113-21. Epub 2011 Apr 25 doi: 10.1002/ijc.25983. PMID: 21328338
Anaesthetic technique may affect prognosis for ovarian serous adenocarcinoma: a retrospective analysis.
Lin L, Liu C, Tan H, Ouyang H, Zhang Y, Zeng W
Br J Anaesth 2011 Jun;106(6):814-22. Epub 2011 Mar 24 doi: 10.1093/bja/aer055. PMID: 21436156
The fallopian tube: primary site of most pelvic high-grade serous carcinomas.
Salvador S, Gilks B, Köbel M, Huntsman D, Rosen B, Miller D
Int J Gynecol Cancer 2009 Jan;19(1):58-64. doi: 10.1111/IGC.0b013e318199009c. PMID: 19258943

Prognosis

Prognostic gene profiles in the tumor microenvironment of ovarian serous adenocarcinoma.
Tian R, Zhao G, Zhou A, Li H, Cao B, Guo S
Front Biosci (Landmark Ed) 2021 Jan 1;26(4):692-705. doi: 10.2741/4913. PMID: 33049689
Expression of PH Domain Leucine-rich Repeat Protein Phosphatase, Forkhead Homeobox Type O 3a and RAD51, and their Relationships with Clinicopathologic Features and Prognosis in Ovarian Serous Adenocarcinoma.
Zhang J, Wang JC, Li YH, Wang RX, Fan XM
Chin Med J (Engl) 2017 Feb 5;130(3):280-287. doi: 10.4103/0366-6999.198932. PMID: 28139510Free PMC Article
Expression of Interactive Genes Associated with Apoptosis and Their Prognostic Value for Ovarian Serous Adenocarcinoma.
Shin K, Kim KH, Yoon MS, Suh DS, Lee JY, Kim A, Eo W
Adv Clin Exp Med 2016 May-Jun;25(3):513-21. doi: 10.17219/acem/62540. PMID: 27629740
DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.
Yamaguchi N, Mimoto R, Yanaihara N, Imawari Y, Hirooka S, Okamoto A, Yoshida K
Tumour Biol 2015 Aug;36(8):5913-23. Epub 2015 Feb 25 doi: 10.1007/s13277-015-3264-y. PMID: 25712377
Anaesthetic technique may affect prognosis for ovarian serous adenocarcinoma: a retrospective analysis.
Lin L, Liu C, Tan H, Ouyang H, Zhang Y, Zeng W
Br J Anaesth 2011 Jun;106(6):814-22. Epub 2011 Mar 24 doi: 10.1093/bja/aer055. PMID: 21436156

Clinical prediction guides

Prognostic gene profiles in the tumor microenvironment of ovarian serous adenocarcinoma.
Tian R, Zhao G, Zhou A, Li H, Cao B, Guo S
Front Biosci (Landmark Ed) 2021 Jan 1;26(4):692-705. doi: 10.2741/4913. PMID: 33049689
Thymidine kinase 1 expression in ovarian serous adenocarcinoma is superior to Ki-67: A new prognostic biomarker.
Wang J, Liu Q, Zhou X, He Y, Guo Q, Shi Q, Eriksson S, Zhou J, He E, Skog S
Tumour Biol 2017 Jun;39(6):1010428317706479. doi: 10.1177/1010428317706479. PMID: 28651488
Demographic Clinical and Prognostic Factors of Primary Ovarian Adenocarcinomas of Serous and Clear Cell Histology-A Comparative Study.
Schnack TH, Høgdall E, Nedergaard L, Høgdall C
Int J Gynecol Cancer 2016 Jan;26(1):82-90. doi: 10.1097/IGC.0000000000000585. PMID: 26569060
Dysregulation of X chromosome inactivation in high grade ovarian serous adenocarcinoma.
Kang J, Lee HJ, Kim J, Lee JJ, Maeng LS
PLoS One 2015;10(3):e0118927. Epub 2015 Mar 5 doi: 10.1371/journal.pone.0118927. PMID: 25742136Free PMC Article
DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.
Yamaguchi N, Mimoto R, Yanaihara N, Imawari Y, Hirooka S, Okamoto A, Yoshida K
Tumour Biol 2015 Aug;36(8):5913-23. Epub 2015 Feb 25 doi: 10.1007/s13277-015-3264-y. PMID: 25712377

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...